Relation between Genomic DNA Breakpoints in MLL Gene and Treatment Outcome in Infants with Acute Leukemia

Aim. To evaluate the relation between genomic DNA breakpoints in MLL and translocation partner genes (TPG) and clinical parameters of infant AL. Methods. 68 infants (29 boys and 39 girls with median age of 4.8 mo) with MLL-rearranged acute lymphoblastic leukemia (ALL) (n = 46), acute myeloid leuk...

Full description

Bibliographic Details
Main Authors: GA Tsaur, C Meyer, TO Riger, AM Kustanovich, EV Fleischman, YuV Ol’shanskaya, AM Popov, OI Sokova, EA Matveeva, OV Nikulina, AE Drui, OR Arakaev, OV Streneva, SA Rumyantsev, EV Shorikov, AG Solodovnikov, LI Savel’ev, R Marschalek, LG Fechina
Format: Article
Language:Russian
Published: Practical Medicine Publishing House 2016-01-01
Series:Kliničeskaâ onkogematologiâ
Subjects:
Online Access:http://bloodjournal.ru/en/relation-between-genomic-dna-breakpoints-in-mll-gene-and-treatment-outcome-in-infants-with-acute-leukemia/
id doaj-0db49f9820234c13a26b0aa3e916b17d
record_format Article
collection DOAJ
language Russian
format Article
sources DOAJ
author GA Tsaur
C Meyer
TO Riger
AM Kustanovich
EV Fleischman
YuV Ol’shanskaya
AM Popov
OI Sokova
EA Matveeva
OV Nikulina
AE Drui
OR Arakaev
OV Streneva
SA Rumyantsev
EV Shorikov
AG Solodovnikov
LI Savel’ev
R Marschalek
LG Fechina
spellingShingle GA Tsaur
C Meyer
TO Riger
AM Kustanovich
EV Fleischman
YuV Ol’shanskaya
AM Popov
OI Sokova
EA Matveeva
OV Nikulina
AE Drui
OR Arakaev
OV Streneva
SA Rumyantsev
EV Shorikov
AG Solodovnikov
LI Savel’ev
R Marschalek
LG Fechina
Relation between Genomic DNA Breakpoints in MLL Gene and Treatment Outcome in Infants with Acute Leukemia
Kliničeskaâ onkogematologiâ
acute leukemia
infants
11q23/MLL rearrangements
MLL-Baby
treatment outcome
author_facet GA Tsaur
C Meyer
TO Riger
AM Kustanovich
EV Fleischman
YuV Ol’shanskaya
AM Popov
OI Sokova
EA Matveeva
OV Nikulina
AE Drui
OR Arakaev
OV Streneva
SA Rumyantsev
EV Shorikov
AG Solodovnikov
LI Savel’ev
R Marschalek
LG Fechina
author_sort GA Tsaur
title Relation between Genomic DNA Breakpoints in MLL Gene and Treatment Outcome in Infants with Acute Leukemia
title_short Relation between Genomic DNA Breakpoints in MLL Gene and Treatment Outcome in Infants with Acute Leukemia
title_full Relation between Genomic DNA Breakpoints in MLL Gene and Treatment Outcome in Infants with Acute Leukemia
title_fullStr Relation between Genomic DNA Breakpoints in MLL Gene and Treatment Outcome in Infants with Acute Leukemia
title_full_unstemmed Relation between Genomic DNA Breakpoints in MLL Gene and Treatment Outcome in Infants with Acute Leukemia
title_sort relation between genomic dna breakpoints in mll gene and treatment outcome in infants with acute leukemia
publisher Practical Medicine Publishing House
series Kliničeskaâ onkogematologiâ
issn 1997-6933
2500-2139
publishDate 2016-01-01
description Aim. To evaluate the relation between genomic DNA breakpoints in MLL and translocation partner genes (TPG) and clinical parameters of infant AL. Methods. 68 infants (29 boys and 39 girls with median age of 4.8 mo) with MLL-rearranged acute lymphoblastic leukemia (ALL) (n = 46), acute myeloid leukemia (AML) (n = 20) and mixed phenotype acute leukemia (MPAL) (n = 2) were included in the current study. Results. 5-year EFS was significantly lower in patients with breakpoints in intron 11 (n = 29) in comparison to patients with breakpoint localized from intron 7 to exon 11 (n = 17) (0.16 ± 0.07 vs 0.38 ± 0.14, p = 0.039). While cumulative incidence of relapse was remarkably higher in the first group of patients (0.74 ± 0.09 vs 0.52 ± 0.17, p = 0.045). Although in Cox regression model including breakpoint location in intron 11 together with age, immunophenotype, initial white blood cell count, initial CNS involvement, type of MLL rearrangements, absolute blast number at day 8 of dexamethasone profase, minimal residual disease (MRD) at time point 4 (TP4) of MLL-Baby protocol, the only significant covariate was the presence of MRD at TP4 (HR 5.994, 95% CI 2.209–16.263, p < 0.001). In 22 AML patients there was not any correlation between breakpoint location and treatment outcome. Conclusion. Breakpoints in intron 11 of MLL gene led to significantly worse outcome in infants with ALL, treated by MLL-Baby protocol, although this parameter was overcome by MRD-positivity at TP4. The latter was the only independent covariate in multivariate analysis. Our data provide additional information of molecular genetic features of MLL-rearranged infant AL.
topic acute leukemia
infants
11q23/MLL rearrangements
MLL-Baby
treatment outcome
url http://bloodjournal.ru/en/relation-between-genomic-dna-breakpoints-in-mll-gene-and-treatment-outcome-in-infants-with-acute-leukemia/
work_keys_str_mv AT gatsaur relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT cmeyer relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT toriger relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT amkustanovich relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT evfleischman relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT yuvolshanskaya relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT ampopov relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT oisokova relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT eamatveeva relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT ovnikulina relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT aedrui relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT orarakaev relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT ovstreneva relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT sarumyantsev relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT evshorikov relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT agsolodovnikov relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT lisavelev relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT rmarschalek relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
AT lgfechina relationbetweengenomicdnabreakpointsinmllgeneandtreatmentoutcomeininfantswithacuteleukemia
_version_ 1725531737826525184
spelling doaj-0db49f9820234c13a26b0aa3e916b17d2020-11-24T23:33:12ZrusPractical Medicine Publishing HouseKliničeskaâ onkogematologiâ1997-69332500-21392016-01-0191222910.21320/2500-2139-2016-9-1-22-29Relation between Genomic DNA Breakpoints in MLL Gene and Treatment Outcome in Infants with Acute LeukemiaGA Tsaur0C Meyer1TO Riger2 AM Kustanovich3EV Fleischman4YuV Ol’shanskaya5AM Popov6OI Sokova7EA Matveeva8OV Nikulina9AE Drui10OR Arakaev11OV Streneva12SA Rumyantsev13EV Shorikov14AG Solodovnikov15LI Savel’ev16R Marschalek17LG Fechina18Regional Children’s Clinical Hospital No. 1, 32 Serafimy Deryabinoi str., Ekaterinburg, Russian Federation, 620149; Research Institute of Medical Cell Technologies, 22a K. Marksa str., Ekaterinburg, Russian Federation, 620026; First President of Russia B.N. Yeltsin Ural Federal University , 19 Mira str., Ekaterinburg, Russian Federation, 620002Diagnostic Center of Acute Leukemia, Institute of Pharmaceutical Biology/ZAFES, Goethe-University of Frankfurt, N230, Max-von-Laue Str. 9, Frankfurt am Main Deutschland, 60438Regional Children’s Clinical Hospital No. 1, 32 Serafimy Deryabinoi str., Ekaterinburg, Russian Federation, 620149; Research Institute of Medical Cell Technologies, 22a K. Marksa str., Ekaterinburg, Russian Federation, 620026Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, 43 Frunzenskaya str., Borovlyany, Minsk District, Belarus, 223053N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Dmitrii Rogachev Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela str., Moscow, Russian Federation, 117198Dmitrii Rogachev Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela str., Moscow, Russian Federation, 117198N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Dmitrii Rogachev Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela str., Moscow, Russian Federation, 117198Regional Children’s Clinical Hospital No. 1, 32 Serafimy Deryabinoi str., Ekaterinburg, Russian Federation, 620149; Research Institute of Medical Cell Technologies, 22a K. Marksa str., Ekaterinburg, Russian Federation, 620026Regional Children’s Clinical Hospital No. 1, 32 Serafimy Deryabinoi str., Ekaterinburg, Russian Federation, 620149; Research Institute of Medical Cell Technologies, 22a K. Marksa str., Ekaterinburg, Russian Federation, 620026Regional Children’s Clinical Hospital No. 1, 32 Serafimy Deryabinoi str., Ekaterinburg, Russian Federation, 620149; Research Institute of Medical Cell Technologies, 22a K. Marksa str., Ekaterinburg, Russian Federation, 620026Regional Children’s Clinical Hospital No. 1, 32 Serafimy Deryabinoi str., Ekaterinburg, Russian Federation, 620149; Research Institute of Medical Cell Technologies, 22a K. Marksa str., Ekaterinburg, Russian Federation, 620026Dmitrii Rogachev Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela str., Moscow, Russian Federation, 117198Regional Children’s Clinical Hospital No. 1, 32 Serafimy Deryabinoi str., Ekaterinburg, Russian Federation, 620149; Research Institute of Medical Cell Technologies, 22a K. Marksa str., Ekaterinburg, Russian Federation, 620026Research Institute of Medical Cell Technologies, 22a K. Marksa str., Ekaterinburg, Russian Federation, 620026Regional Children’s Clinical Hospital No. 1, 32 Serafimy Deryabinoi str., Ekaterinburg, Russian Federation, 620149; Research Institute of Medical Cell Technologies, 22a K. Marksa str., Ekaterinburg, Russian Federation, 620026Diagnostic Center of Acute Leukemia, Institute of Pharmaceutical Biology/ZAFES, Goethe-University of Frankfurt, N230, Max-von-Laue Str. 9, Frankfurt am Main Deutschland, 60438Regional Children’s Clinical Hospital No. 1, 32 Serafimy Deryabinoi str., Ekaterinburg, Russian Federation, 620149Aim. To evaluate the relation between genomic DNA breakpoints in MLL and translocation partner genes (TPG) and clinical parameters of infant AL. Methods. 68 infants (29 boys and 39 girls with median age of 4.8 mo) with MLL-rearranged acute lymphoblastic leukemia (ALL) (n = 46), acute myeloid leukemia (AML) (n = 20) and mixed phenotype acute leukemia (MPAL) (n = 2) were included in the current study. Results. 5-year EFS was significantly lower in patients with breakpoints in intron 11 (n = 29) in comparison to patients with breakpoint localized from intron 7 to exon 11 (n = 17) (0.16 ± 0.07 vs 0.38 ± 0.14, p = 0.039). While cumulative incidence of relapse was remarkably higher in the first group of patients (0.74 ± 0.09 vs 0.52 ± 0.17, p = 0.045). Although in Cox regression model including breakpoint location in intron 11 together with age, immunophenotype, initial white blood cell count, initial CNS involvement, type of MLL rearrangements, absolute blast number at day 8 of dexamethasone profase, minimal residual disease (MRD) at time point 4 (TP4) of MLL-Baby protocol, the only significant covariate was the presence of MRD at TP4 (HR 5.994, 95% CI 2.209–16.263, p < 0.001). In 22 AML patients there was not any correlation between breakpoint location and treatment outcome. Conclusion. Breakpoints in intron 11 of MLL gene led to significantly worse outcome in infants with ALL, treated by MLL-Baby protocol, although this parameter was overcome by MRD-positivity at TP4. The latter was the only independent covariate in multivariate analysis. Our data provide additional information of molecular genetic features of MLL-rearranged infant AL.http://bloodjournal.ru/en/relation-between-genomic-dna-breakpoints-in-mll-gene-and-treatment-outcome-in-infants-with-acute-leukemia/acute leukemiainfants11q23/MLL rearrangementsMLL-Babytreatment outcome